View all adult cancer types
View all pediatric cancer types
Susan F. Smith Center for Women's Cancers
Gynecologic CancerBlood CancersCancer Genetics and PreventionCutaneous (Skin) CancerGastrointestinal CancerGenitourinary CancerHead and Neck CancerHematologyMelanomaNeuro-OncologySarcomaStem Cell TransplantThoracic (Lung) Cancer
Blood DisordersBrain TumorsHematologic MalignanciesSolid TumorsStem Cell Transplant
In an affirmation of worldwide respect for the impact of Dana-Farber research, 19 basic scientists and clinical investigators at the Institute have been listed among "the world's most influential scientific minds." The ranking was based on how frequently their research discoveries have been cited by peers in the past decade.
Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.
Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.
Research led by Bruce Spiegelman, PhD, and colleagues shows that adipsin, a cell signaling protein made by fat cells, plays a critical, previously unsuspected role in stimulating insulin secretion to control blood sugar, and the discovery could have implications for treatment of type 2 diabetes.
Dana-Farber Cancer Institute is acquiring the Commonwealth Hematology-Oncology (CHO) physician practice and extending its sophisticated cancer care model further into the community, effective July 1, 2014.
Eric P. Winer co-chaired an expert panel that developed a clinical practice
guideline on disease management for patients with advanced HER2-positive breast
cancer and brain metastases.
E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine
significantly prolonged progression-free survival in patients with progressive
HER2-positive advanced breast cancer.
Dr. Matthew Meyerson
led a genomic study of lung cancer which has provided information that could
help scientists devise new treatments.
Paul L. Nguyen led a study showing prostate cancer patients with health
insurance are less likely to have metastatic disease or die from the
cancer than those without health insurance.
Robert Haddad commented on JPMorgan Chase CEO Jamie Dimon being diagnosed with throat cancer.
Dr. Joyce Liu commented on the Oncologic Drugs Advisory Committee vote to delay approval of the PARP inhibitor olaparib.
Johnson & Johnson Innovation Center will fund a $10 million partnership with Dana-Farber and Janssen Biotech to work on lung cancer immunotherapy drugs.
Breast Cancer Support Group-Milford(3)
4:30 PM - 5:30 PM
20 Prospect Street, 2nd Floor
An opportunity for women who would like to meet with others to explore ways to cope with their diagnosis and its effect on their lives through education and support.
Call Ann Sullivan at 508-488-3783 to register.
This program is free and refreshments will be provided.
Caring for the Caregiver-Milford(3)
6:00 PM - 7:00 PM
This is a support group for those who have a loved one or friend with cancer. The program will provide practical information to support you in your role as a caregiver, as well as offer an opportunity to meet and gain support from others coping with similar issues.
Call Ann Sullivan, LICSW at 508-488-3783 to register.
Sarcoma Support Group(2)
12:30 PM - 1:30 PM
Smith Building, Room 330
This group is an opportunity to share information, coping skills and network with other Sarcoma patients and their caregivers.
Patient referral information, clinical resources and more.
For adults:877-442-3324For children:888-733-4662Or complete the online form.
Search current cancer clinical trials at Dana-Farber.
There are many ways to support Dana-Farber and the Jimmy Fund.
More ways to helpGiving Catalog
Insight features the latest in cancer care and research news from Dana-Farber.Read the blog
Stay current on the latest news by signing up for Spotlight, our email newsletter.View current issueSubscribe now
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: